Put the life science ecosystem to work for you in Boston

May 28, 2015 Erin Righetti

iStock_000023106471_LargeENGAGE and DE-RISK.

These two terms describe the enormous task of drug development, which is best achieved by wide engagement across the life science ecosystem, to distribute risk that can otherwise be overwhelming.

Add to that description “DISRUPT.”

There is an increasing number of industry heavy hitters who have successfully led and exited large corporations and are now investing their experience, clout and in some cases, personal finances to reseed the life science ecosystem by leading the charge at small companies.

This is the topic of the BioPharm America™ opening plenary entitled “Giving up the corporate jet and going back to the trenches: Insights from biotech disrupters” taking place September 15, 2015. The plenary will be moderated by Francois Maisonrouge, Senior Managing Director at Evercore Partners, who is joined by speakers Deborah Dunsire, President and CEO at FORUM Pharmaceuticals; Jeremy Levin, Chairman and CEO at Ovid Therapeutics Inc.; and Christopher A. Viehbacher, Member of the Board of Directors at PureTech, and Chairman at Vedanta.

These four disrupters left big pharma behind to join small biotech companies and drive innovation that is on the front lines of drug development. Their experiences provide perspectives from both sides of the fence, and they have real “war stories” to share about how they got to where they are now.

But these innovative executives are just one component of the drug development ecosystem microcosm made up of serial entrepreneurs, global finance, pharma, service and commercialization partners who attend the event. BioPharm America 2015 plays an essential role in forging vital partnerships across the life science ecosystem for the benefit of each player, and the industry at large. The plenary is just one element that will kick off a wholly reimagined event this year with new initiatives and program elements designed to bring all the key ecosystem stakeholders to the partnering table, such as:

  • Quick pitches by disruptive startups from Boston and around the globe during Biotech Startup Day;
  • Presentations by top biotech companies vetted by a committee of pharma scouts;
  • Opportunities to engage with dealmakers at five pharma lounges;
  • Partnerships in Regenerative Medicine and Advanced Therapies summit;
  • Programs for venture philanthropy and other alternative partners/investors; and
  • Tour/meetings with local research centers and universities.

There won’t be a better time this year to engage with the rich life science ecosystem. Register now and plan your Boston week this September 15–17 to see what’s new.




Previous Article
Despite slow start to 2015 clinical activity, rates predicted to go up

Guest post by Surani Fernando, Acting Editor, EMEA, BioPharm Insight BioPharm Insight‘s Clinical Activity R...

Next Article
Where Are They Now? The Life Sciences Report Small-Cap Watchlist Edition

Guest post by Jim Patrick, Publisher, The Life Sciences Report It’s been four months since Streetwise Repor...